Cargando…
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase pr...
Autores principales: | Wang, Beike, Zhang, Wei, Zhang, Gao, Kwong, Lawrence, Lu, Hezhe, Tan, Jiufeng, Sadek, Norah, Xiao, Min, Zhang, Jie, Labrie, Marilyne, Randell, Sergio, Beroard, Aurelie, Sugarman, Eric, Rebecca, Vito W., Wei, Zhi, Lu, Yiling, Mills, Gordon B., Field, Jeffrey, Villanueva, Jessie, Xu, Xiaowei, Herlyn, Meenhard, Guo, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445818/ https://www.ncbi.nlm.nih.gov/pubmed/34304249 http://dx.doi.org/10.1038/s41388-021-01911-5 |
Ejemplares similares
-
PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017) -
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011) -
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015) -
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020) -
BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)